|
The Edinburgh Cancer Research Centre (ECRC), also known as the Edinburgh Cancer Research UK Centre and the University of Edinburgh Cancer Research Centre, is a world-class center for basic, translational and clinical cancer research located in Edinburgh, Scotland. ECRC constitutes an integral part of the (Institute of Genetics & Molecular Medicine ) (IGMM) and is positioned in direct proximity of the Western General Hospital, where most of its clinical activities take place. The ECRC is also a member of the (Experimental Cancer Medicine Centre (ECMC) Network ). ==Scientific activities== A broad spectrum of tumor types are studied in the Centre although the main strengths of ECRC lay in the areas of breast, colorectal and ovarian cancers. They include research focused on: * Stem cells and the cancer stem cell niche * Signal transduction and biological mechanisms * Lifestyle, risk and prevention * Stratification for prevention and therapy In these fields the ECRC has gained international recognition as a cutting-edge research center of excellence in innovative biomedical research and belongs to the Cancer Research UK Centres network of excellence. The ECRC investigators play also an important role in the palliative care practice and research.〔(【引用サイトリンク】url=http://www.youtube.com/watch?v=nkWbTWOQ8iM )〕 As of 2015, research in the ECRC is carried out by 27 independent but highly interactive research teams. In addition, 9 clinical researchers and 14 affiliated research groups are associated with the Centre.〔(【引用サイトリンク】url=http://www.ecrc.ed.ac.uk/Researchers.html )〕 Several technology platforms, including reverse phase protein arrays and advanced microscopy, support the research activities with cutting-edge technology.〔(【引用サイトリンク】 url=http://www.ecrc.ed.ac.uk/facilities/facilities-overview.html )〕 Since 2011, the ECRC also hosts a dedicated drug discovery unit.〔(【引用サイトリンク】 url=http://www.ecrc.ed.ac.uk/discovery-unit/overview.html )〕 Since 2010, the institute is led by Margaret Frame (as the Science Director) and David Cameron (as the Clinical Director) with help and advise from the ECRC Governance Board. Recent highlights from ECRC scientists and clinicians include: * Important role (David Cameron as joint global Chief Investigator) in the pivotal clinical trial that tested the hypothesis that the combination of lapatinib and the cytotoxic drug capecitabine would be superior to capecitabine alone in patients with HER2+ metastatic breast cancer that had progressed despite trastuzumab treatment. The results of this trial has led to a global (more than 100 countries) marketing authorisation of the drug lapatinib produced by the pharmaceutical company GlaxoSmithKline. * BRCA1/BRCA2 deficient ovarian cancer - identification of a unique clinical phenotype and development of individualised therapy. * Identification of new gene variants linked to colorectal cancer. * Evidence-based identification of an effective treatment of depression in cancer patients. * Evidence that Focal Adhesion Kinase, a protein that regulates cell adhesion, is also involved in regulation of autophagy, a potential cancer cell survival mechanism. * Evidence that oncogenic-stress can cause Focal Adhesion Kinase (FAK) to move to the nucleus to regulate expression of genes (chemokines & cytokines) that promote tumor evasion by inducing an immuno-suppresive microenvironment, and demonstration that FAK inhibitor in clinical development can help the body's immune system to fight cancer. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Edinburgh Cancer Research Centre」の詳細全文を読む スポンサード リンク
|